FindTrial
Sign In

A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee

A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220732
Enrollment
Unknown
Registered
2009-05-13
Start date
2009-05-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

investigational material(s) Generic name etc : AZD1386 INN of investigational material : Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Administratio

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with OA of the knee

Exclusion criteria

Exclusion criteria: - A current diagnosis of another form of arthritis, in addition to OA - History, and/or presence of somatic disease, which may interfere with the objectives

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026